Chief Medical Officer Birgitte Volck to leave Sobi

To join GlaxoSmithKline as Head of R&D Rare Diseases

Birgitte Volck, Senior Vice President of Development and Chief Medical Officer (CMO) at Swedish Orphan Biovitrum (Sobi) is leaving the company to join the rare disease research group at GlaxoSmithKline as Head of R&D Rare Diseases. Volck will work through a six-month notice period before leaving the company.

'We thank Birgitte for her leadership and dedication which has helped to evolve Sobi's patient oriented research and development organisation into a highly skilled international team,' said Geoffrey McDonough, President and CEO of Sobi.

Volck joined Sobi in 2012 and has been instrumental in advancing the firm's late stage development projects and in bringing new treatment options to people with rare diseases, he added.

You may also like

Manufacturing

GSK bolsters its US drug manufacturing capabilities with $800m investment

The expansion will double the size and capacity of its Marietta site, supporting the manufacture of sterile liquid vaccines and production for clinical trials
Manufacturing

GSK licenses Touchlight's enzymatic dbDNA for optimised mRNA vaccine production

GSK will now have non-exclusive rights to the use of dbDNA for efficient commercial DNA and mRNA production
Manufacturing

GSK and Pistoia Alliance announce laboratory tech to improve reproducibility

Founded by Pistoia Alliance and now implemented at GSK, the Methods Hub is a digital tool that enables the instant transfer and overlaying of analytical methods
Regulatory

GSK's respiratory syncytial virus vaccine receives approval

The MHRA has authorised has authorised Arexvy (respiratory syncytial virus vaccine, adjuvanted) for immunisation for LRTD in adults 60 years or older
Manufacturing

Wood wins significant $50m US Life Sciences project with GSK

Wood’s three-year contract will support GSK’s production of innovative specialty medicines for the US and globally as part of GSK’s plan to develop the site
Manufacturing

Tickets now on sale for 2023 Manufacturing Chemist Live

Super early bird tickets are now on sale for the annual conference due to take place in Birmingham on 24 – 25 May 2023
Ingredients

Therapeutic: efanesoctocog alfa for haemophilia A

Haemophilia A is a rare genetic disorder in which the blood cannot clot properly; this is caused by a lack of factor VIII, one of the proteins involved in the clotting cascade
Subscribe now